Organon Reports Q1 2025 Revenue Decline and Guidance

Organon ( (OGN) ) has shared an announcement.

On May 1, 2025, Organon announced its first-quarter financial results, revealing a revenue decline of 7% compared to the previous year, with total revenue of $1.513 billion. The company declared a reduced quarterly dividend and affirmed its financial guidance for 2025, focusing on deleveraging and capital structure improvement. Key growth drivers, Nexplanon and Vtama, are on track to meet their revenue targets, while the company aims to generate over $900 million in free cash flow before one-time costs.

Spark’s Take on OGN Stock

According to Spark, TipRanks’ AI Analyst, OGN is a Neutral.

Organon’s overall stock score reflects strong operational capacity and cash flow but is offset by high leverage and declining net income. The stock is technically weak but offers potential upside due to its attractive valuation. The earnings call and recent board appointment provide a mixed but cautiously optimistic outlook.

To see Spark’s full report on OGN stock, click here.

More about Organon

Organon operates in the pharmaceutical industry, focusing on women’s health, biosimilars, and established brands. The company is committed to enhancing its portfolio with products like Nexplanon and Vtama, and aims to strengthen its financial structure through strategic capital allocation.

YTD Price Performance: -11.74%

Average Trading Volume: 3,977,953

Technical Sentiment Signal: Buy

Current Market Cap: $3.36B

For a thorough assessment of OGN stock, go to TipRanks’ Stock Analysis page.